Clinical Trial

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)

Study acronym: DESAR-L
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase. The investigator plans to evaluate grade 1 or higher rectal bleeding occurring within 3 years in patients who have received low -fractionation curative radiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-11.
Trial Details
NCT Number NCT06461819
Lead Sponsor Samsung Medical Center
Conditions Low-to-intermediate-risk Prostate Carcinoma
Enrollment 33 participants
Start Date 2023-08-11
Primary Completion 2033-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-21